BiVictriX taps Glyn Baker as its new finance chief

Cancer therapy biotechnology company BiVictriX Therapeutics announced the appointment of Glyn Baker as its chief financial officer on Thursday, in a non-board role.

The AIM-traded firm said Baker had worked in the biotechnology industry for around 20 years, initially as a financial and IT consultant before moving to various senior finance management roles.

Most recently, he had been involved in establishing a new Cambridge-based start-up in the neurodegenerative disease space.

Prior to that, Baker was finance director of drug discovery company Inflazome, where he managed a €40m series-B investment round and arranged a $20m venture debt facility with Oxford Finance, based in Boston, Massachusetts.

In 2020, Inflazome was bought by Roche for an upfront payment of $450m, plus substantial milestones.

BiVictriX said Baker was part of the Inflazome board sub-committee managing relationships with investors, potential exit partners and a range of intermediaries.

Before joining Inflazome, Baker was the CFO of TwistDx, which was sold to Alere in March 2010, which itself was subsequently acquired by Abbott Laboratories in February 2016.

Laura Brogden, the company's financial controller, would remain with BiVictriX for a period of three months to ensure an orderly handover of responsibilities to Baker.

“We are delighted to welcome Glyn Baker to BiVictriX as chief financial officer,” said chief executive officer Tiffany Thorn.

“Glyn has amassed significant expertise in finance and mergers and acquisitions over the last 20 years, with some impressive accomplishments.

“This knowledge, coupled with his contacts, will be invaluable as we look to grow our business and progress the development of our Bi-Cygni therapeutics.”

Glyn Baker added that he was “particularly attracted” to BiVictriX due to its “quality of science”, the leadership team and its board of directors.

“I look forward to supporting Tiffany and the broader team as the company progresses the development of its key work programmes.”

At 1411 GMT, shares in BiVictriX Therapeutics were up 1.69% at 30p.